The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Casolaro, Alessia ^a   Golay, Josee ^b   Albanese, Clara ^a   Ceruti, Roberta ^a   Patton, Veronica ^a   Cribioli, Sabrina ^a   Pezzoni, Alice ^c   Losa, Marco ^d   Texido, Gemma ^a   Giussani, Ursula ^b   Marchesi, Francesco ^e   Amboldi, Nadia ^a   Valsasina, Barbara ^a   Bungaro, Silvia ^f   Cazzaniga, Gianni ^f   Rambaldi, Alessandro ^b   Introna, Martino ^b   Pesenti, Enrico ^a   Alzani, Rachele ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d Pathology   (Italy)

^e Accelera Srl   (Italy)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CYTARABINE; DOXORUBICIN; NMS P 937; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE MONOCYTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CASE REPORT; CELL EXPANSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENOTYPE; HUMAN; HUMAN CELL; IC 50; KARYOTYPE; LEUKEMIA CELL; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; ANIMALS; ANTIGENS, CD56; CELL CYCLE PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; QUINAZOLINES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874761718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058424     Document Type: Article

References (38)

1. Estey E, Döhner H, (2006) Acute myeloid leukaemia. Lancet 368 (9550): 1894-1907.
2. Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, et al. (2007) End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109 (5): 1810-1816.
3. Löwenberg B, Downing JR, Burnett AN, (1999) Acute myeloid leukemia. Engl J Med 341 (14): 1051-1062.
4. Suela J, Alvarez S, Cifuentes F, Largo C, Ferreira BI, et al. (2007) DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 21(6): 1224-1231.
5. Döhner H, Gaidzik VI (2011) Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program: 36-42.
6. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, et al. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 (7218): 66-72.
7. Greif PA, Eck SH, Konstandin NP, Benet-Pagès A, Ksienzyk B, et al. (2011) Identification of recurring tumour-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia 25 (5): 821-827.
8. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, et al. (2002) Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 87 (3): 250-256.
9. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, et al. (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90 (4): 1643-1648.
10. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, et al. (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15 (8): 1161-1164.
11. Chang H, Brandwein J, Qi-Long Y, Chun K, Patterson B, et al. (2004) Extramedullary infiltrates of AML are associated with CD56 expression, 11q 23 abnormalities and inferior clinical outcome. Leukemia Res 28: 1007-1011.
12. Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, et al. (2009) Mouse models of human AML accurately predict chemotherapy response. Gene Dev 23 (7): 877-889.
13. Tsykunova G, Reikvam H, Ahmed AB, Nepstad I, Gjertsen BT, et al. (2012) Targeting of polo-like kinases and their cross talk with Aurora kinases-possible therapeutic strategies in human acute myeloid leukemia? Expert Opin Investig Drugs 21 (5): 587-603.
14. Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, et al. (2012) NMS-P937, an orally available, specific small molecule Polo-Like Kinase 1 inhibitor with antitumour activity in solid and haematological malignancies. Mol Cancer Ther 11 (4): 1006-1016.
15. Renner AG, Dos Santos C, Recher C, Bailly C, Créancier L, et al. (2009) Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 114 (3): 659-662.
16. Lee EM, Bachmann PS, Lock RB, (2007) Xenograft models for the preclinical evaluation of new therapies in acute leukaemia. Leukemia & Lymphoma 48 (4): 659-668.
17. Giavazzi R, Di Berardino C, Garofalo A, Motta T, Gobbi A, et al. (1995) Establishment of human acute myelogenous leukemia lines secreting interleukin-1 beta in SCID mice. Int J Cancer 61: 280-285.
18. Golay J, Di Gaetano N, Amico D, Cittera E, Barbui AM, et al. (2005) Gemtuzumab ozogamicin(Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 128: 310-317.
19. Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, et al. (2012) Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 26(7): 1517-1526.
20. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, et al. (1992) The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 5: 827-836.
21. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ, (1997) Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89 (9): 3104-3112.
22. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (6464): 645-648.
23. Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, et al. (2011) NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 21 (10): 2969-2974.
24. Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, et al. (2009) Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol 24 (7): 879-891.
25. Bardini M, Galbiati M, Lettieri A, Bungaro S, Gorletta TA, et al. (2011) Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia 25 (1): 175-178.
26. Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, et al. (2009) A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 23 (9): 1564-1576.
27. Strebhardt K, Ullrich A, (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6 (4): 321-330.
28. Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R, et al. (2010) Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Res 30 (12): 4973-4985.
29. Rocco JW, Sidransky D, (2001) p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 264 (1): 42-55.
30. Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, et al. (2009) Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA 106 (31): 12950-12955.
31. Li Z, Chen Z, Lu J, Cen J, He J, et al. (2006) Establishment of a nude mice model of human monocytic leukemia with CNS and multiorgan extramedullary infiltration. Eu J Haematol 77: 128-133.
32. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (2008) Acute myeloid leukaemia not otherwise categorized. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and genetics of Tumours of Haematopoietic and Lymphoid Tissues. Volume 2, Fourth edition, IARC Press. 91-105.
33. Delgado J, Morado M, Jimenez MC, Garcia-Grande A, Hernandez-Navarro F, (2002) CD56 expression in myeloperoxidase-negative FAB M5 acute myeloid leukemia. Am J Haematol 69 (1): 28-30.
34. Novontny JR, Nuckel H, Duhrsen U, (2006) Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia. Eur J Haematol 76: 299-308.
35. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, et al. (2002) CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res 26 (7): 643-649.
36. Gattenloehner S, Chuvpilo S, Langebrake C, Reinhardt D, Muller-Hermelink HK, et al. (2007) Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. Blood 110 (6): 2027-2033.
37. McInnes C, Wyatt MD, (2011) PLK1 as an oncology target: current status and future potential. Drug Discov Today 16(13-14): 619-625.
38. Berg T, Bug G, Ottmann OG, Strebhardt K, (2012) Polo-like kinases in AML. Expert Opin Investig Drugs 21(8): 1069-74.